Last reviewed · How we verify

Kalcipos-D

Takeda · FDA-approved active Small molecule

Kalcipos-D combines calcipotriol (a vitamin D analog) with calcium carbonate to regulate calcium and phosphate metabolism and promote bone mineralization.

Kalcipos-D combines calcipotriol (a vitamin D analog) with calcium carbonate to regulate calcium and phosphate metabolism and promote bone mineralization. Used for Hypocalcemia and vitamin D deficiency, Secondary hyperparathyroidism, Osteoporosis prevention and treatment.

At a glance

Generic nameKalcipos-D
SponsorTakeda
Drug classVitamin D analog with calcium supplement
TargetVitamin D receptor (VDR)
ModalitySmall molecule
Therapeutic areaEndocrinology / Bone Metabolism
PhaseFDA-approved

Mechanism of action

Calcipotriol is a synthetic vitamin D3 analog that binds to vitamin D receptors to enhance intestinal calcium absorption and regulate serum calcium and phosphate levels. The addition of calcium carbonate provides supplemental elemental calcium. Together, these components work to correct hypocalcemia and support bone health in patients with vitamin D deficiency or impaired calcium metabolism.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: